Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 3/20 | 0.65 |
| ▸ | BRAF | P15056 | 16/20 | 0.58 |
| ▸ | PDE4A | P27815 | 12/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.58 |
| ▸ | EEF2K | O00418 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176552 | 0.87 | IKBKB (0.70) | IKBKBBRAFPDE4APDE4BPDE4C | |
| SCHEMBL1176187 | 0.87 | IKBKB (0.67) | IKBKBBRAFPDE4APDE4BPDE4C | |
| SCHEMBL3406686 | 0.85 | IKBKB (0.47) | IKBKBBRAFPDE4APDE4BPDE4C | |
| SCHEMBL1176215 | 0.85 | IKBKB (0.54) | IKBKBBRAFPDE4APDE4BPDE4C | |
| SCHEMBL1175603 | 0.84 | IKBKB (0.64) | IKBKBBRAFPDE4APDE4BPDE4C | |
| SCHEMBL12871394 | 0.82 | BRAF (0.58) | IKBKBBRAFPDE4APDE4BPDE4C | |
| SCHEMBL1176255 | 0.82 | IKBKB (0.60) | IKBKBBRAFPDE4APDE4BPDE4C | |
| SCHEMBL1176017 | 0.81 | LIMK1 (0.60) | IKBKBBRAFPDE4APDE4BPDE4C | |
| SCHEMBL1176286 | 0.81 | IKBKB (0.62) | IKBKBBRAFPDE4APDE4BPDE4C | |
| SCHEMBL1176329 | 0.80 | IKBKB (0.58) | IKBKBBRAFPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | claimed |
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028472-A1 | THIENOPYRIMIDINES | TGFBR1, TYMP, TGFBR2 | IKBKB 351/4885BRAF 183/4885PDE4A 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.